ClinicalTrials.gg
CompletedNCT05670730EXPLORE44Updated Jul 14, 2025

Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping

A Phase 1/2 interventional study of AOC 1044 and Placebo in Duchenne Muscular Dystrophy and Exon 44, sponsored by Avidity Biosciences, Inc.. Completed at 10 sites in United States. Open to male participants aged 7 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Avidity Biosciences, Inc. (part of Novartis) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 1 year 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
7 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 61 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
42nd of 172
70 · median 25
Started
2022
with 14 others
Phase 1/2
25 of 233
3 open now
Registered
188th of 233
by date

Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 42nd largest by enrollment of the 172 interventional ones that give a count, is one of 15 that started in 2022, is one of 25 in phase 1/2, and was the 188th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 7 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

AOC 1044-CS1 (EXPLORE44) is a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of AOC 1044 in healthy adult volunteers and participants with DMD mutations amenable to exon 44 skipping.

Part A is a single dose design with multiple cohorts (dose levels) in healthy adult volunteers.

Part B is a multiple-ascending dose design with 3 cohorts (dose levels) in participants with Duchenne.

03

Conditions studied

  • Duchenne Muscular Dystrophy
  • Exon 44

Keywords

  • EXPLORE44
  • Avidity Biosciences
  • Avidity
  • AOC 1044
04

Who can participate

Ages eligible
7 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Part A:

Key Inclusion Criteria:

  • Aged 18 to 55 years, inclusive, at the time of
  • (BMI) of 18.5 to 32.0 kg/m2

Key Exclusion Criteria:

  • abnormalities in laboratory results, ECGs, or vitals
  • Current or recent use of prescription or nonprescription drugs
  • Positive drug/alcohol test at Screening or Day -1
  • Elevated blood pressure (BP) >130/80 mmHg at Screening
  • Participation in a clinical study in which an product was received within 1 month of screening or 5 half-lives of the investigational product
  • Blood or plasma donation within 16 weeks of planned AOC 1044 administration Note: Other protocol defined Inclusion/Exclusion criteria may apply

Part B:

Key Inclusion Criteria:

  • Aged 7 to 27 years, inclusive, at the time of informed consent
  • Clinical diagnosis of DMD or clear onset of DMD symptoms at or before the age of 6 years
  • Confirmation of DMD gene mutation amenable to exon 44 skipping
  • Weight ≥ 23 kg
  • Ambulatory or non-ambulatory

    • Ambulatory participants: ≥50% and FVC≥50%
    • Non-ambulatory participants: LVEF ≥45% and FVC≥40%
  • PUL 2.0 entry item A ≥3
  • If on , stable dose for 30 days before screening and throughout the study

Key Exclusion Criteria:

  • Biceps brachii muscles unsuitable for
  • Serum \< lower limit of normal
  • Uncontrolled hypertension or diabetes
  • Prior treatment with any cell or gene therapy
  • Prior treatment with another exon 44 skipping agent within 6 months prior to informed consent
  • Recently treated with an investigational drug
  • History of multiple drug allergies
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    AOC 1044-CS1 Part A - Single Dose Levels 1-5

    AOC 1044 will be administered once.

    Drug: AOC 1044

  • Placebo comparator
    AOC 1044-CS1 Part A - Single Dose: Placebo

    Placebo will be administered once.

    Drug: Placebo

  • Experimental
    AOC 1044-CS1 Part B - Multiple Ascending Dose Levels 1-3

    AOC 1044 will be administered three times.

    Drug: AOC 1044

  • Placebo comparator
    AOC 1044-CS1 Part B - Multiple Ascending Dose: Placebo

    Placebo will be administered three times.

    Drug: Placebo

Interventions

  • AOC 1044 will be administered via intravenous (IV) infusion

  • DrugPlacebo

    Placebo will be administered via intravenous (IV) infusion.

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Through study completion, up to Day 85 (Part A) or Day 169 (Part B)

Secondary outcomes

  1. Plasma pharmacokinetic (PK) parameters

    Maximum plasma concentration (Cmax) of AOC 1044

    Time frame: Through Week 8 (Part A); Through Week 12 (Part B)

  2. Plasma pharmacokinetic (PK) parameters

    Terminal half-life (T1/2) of AOC 1044

    Time frame: Through Week 8 (Part A); Through Week 12 (Part B)

  3. Plasma pharmacokinetic (PK) parameters

    Area under the concentration-time curve (AUC) of AOC 1044

    Time frame: Through Week 8 (Part A); Through Week 12 (Part B)

  4. PMO44 levels in skeletal muscle tissue

    Time frame: Through Week 4 (Part A); Through Week 16 (Part B)

  5. Urine pharmacokinetic parameters

    Fraction of PMO44 excreted in urine

    Time frame: Day 1-2 (0-24 hours after first dose) (Part A); Day 1-2 (0-24 hours after first dose) (Part B)

  6. Change from baseline in exon skipping as measured in skeletal muscle (Part B only)

    Time frame: Baseline, Week 16

  7. Absolute change from baseline in dystrophin protein level in skeletal muscle (Part B only)

    Time frame: Baseline, Week 16

  8. Percentage change from baseline in dystrophin protein level in skeletal muscle (Part B only)

    Time frame: Baseline, Week 16

07

Study locations

10 sites
  • Arkansas Children's
    Little Rock, Arkansas 72202, United States
  • UCSD
    La Jolla, California 92037, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Rare Disease Research - Atlanta
    Atlanta, Georgia 30329, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Massachusetts Chan Medical School
    Worcester, Massachusetts 01655, United States
  • Gillette Children's
    Saint Paul, Minnesota 55101, United States
  • Rare Disease Research NC
    Hillsborough, North Carolina 27278, United States
  • Abigail Research Institute at Nationwide Children's Hospital
    Columbus, Ohio 43215, United States
  • Worldwide Clinical Trials (Part A only)
    San Antonio, Texas 78217, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Nov 2024, 24 months.

Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2022
First posted
Jan 4, 2023
StartActual
Nov 9, 2022
Primary completionActual
Nov 25, 2024
CompletionActual
Nov 25, 2024
Results delay requested
Jul 10, 2025
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05670730
Responsible party
Sponsor
First posted
Jan 4, 2023
Start date
Nov 9, 2022
Primary completion
Nov 25, 2024
Completion
Nov 25, 2024
Last update
Jul 14, 2025

Study contacts

Carmen Castrillo, MD
study director · Avidity Biosciences, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delpacibart zotadirsen

Start the discussion